Business Description
Biohaven Ltd
NAICS : 541714
SIC : 2834
Description
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, immunology, and disease-related biology, including rare disorders. Its neuroscience portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7, glutamate receptors, myostatin, and TRP channels. Its products target diseases such as migraine, depression, bipolar, and schizophrenia.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 11.51 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 22.15 | |||||
| 9-Day RSI | 30.89 | |||||
| 14-Day RSI | 35.28 | |||||
| 6-1 Month Momentum % | 54.25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.94 | |||||
| Quick Ratio | 4.94 | |||||
| Cash Ratio | 3.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -1.65 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -122.34 | |||||
| ROA % | -95.5 | |||||
| ROIC % | -465.58 | |||||
| ROC (Joel Greenblatt) % | -1121.22 | |||||
| ROCE % | -120.95 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.96 | |||||
| Price-to-Tangible-Book | 3.12 | |||||
| EV-to-EBIT | -1.85 | |||||
| EV-to-EBITDA | -1.87 | |||||
| EV-to-FCF | -2.84 | |||||
| Price-to-Net-Current-Asset-Value | 3.67 | |||||
| Price-to-Net-Cash | 5.36 | |||||
| Earnings Yield (Greenblatt) % | -54.05 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:BHVN
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biohaven Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -7.47 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 35.28 | ||
| 14-Day ATR ($) | 0.929814 | ||
| 20-Day SMA ($) | 18.501 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 5.54 - 26.64 | ||
| Shares Outstanding (Mil) | 68.32 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biohaven Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biohaven Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Biohaven Ltd Frequently Asked Questions
What is Biohaven Ltd(BHVN)'s stock price today?
The current price of BHVN is $16.77. The 52 week high of BHVN is $26.64 and 52 week low is $5.54.
When is next earnings date of Biohaven Ltd(BHVN)?
The next earnings date of Biohaven Ltd(BHVN) is 2023-11-09 Est..
Does Biohaven Ltd(BHVN) pay dividends? If so, how much?
Biohaven Ltd(BHVN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers